Arcus Biosciences reported Nature-published data connecting circulating erythropoietin dynamics to treatment response in patients with metastatic clear cell renal cell carcinoma receiving casdatifan. The company’s ARC-20 study evaluated the next-generation HIF-2α inhibitor as monotherapy and highlights biomarkers tied to downstream pathway effects. The results, published in Nature, aim to clarify how HIF-2α blockade translates into measurable pharmacodynamic changes, including effects on circulating erythropoietin. Arcus said the dataset supports a mechanistic framework for response evaluation in advanced ccRCC. The reporting also complements clinical development efforts for casdatifan, including translational work intended to refine patient stratification and help interpret efficacy signals during ongoing trials. For kidney cancer developers, the release adds evidence that pathway biomarkers can be operationally useful in HIF-2α programs, reinforcing the trend toward biomarker-informed clinical readouts in targeted oncology.